Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$468.63 USD

468.63
827,133

-9.21 (-1.93%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $468.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?

Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.

National Vision (EYE) Hurt by Rising Costs, Vendor Dependency

High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.

Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays

According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.

Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research

Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.

Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

Style Box ETF report for IWP

Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair

Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.

Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Encompass Health's (EHC) Nationwide Hospital Count Rises to 147

Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.

Here's Why You Should Retain Edwards Lifesciences (EW) Now

Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.

Reasons to Add Allscripts (MDRX) Stock to Your Portfolio

Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.

Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?

Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).

Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?

Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).

Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?

Style Box ETF report for IWR

Idexx (IDXX) Down 0.1% Since Last Earnings Report: Can It Rebound?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mark Vickery headshot

Top Analyst Reports for salesforce, General Motors & Block

Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, inc. (CRM), General Motors Company (GM), and Block, Inc. (SQ).

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.

IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays

IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up

Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.

Idexx Laboratories (IDXX) Tops Q4 Earnings and Revenue Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 13.17% and 2.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN

The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.

IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.

Analysts Estimate Idexx Laboratories (IDXX) to Report a Decline in Earnings: What to Look Out for

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?

Style Box ETF report for IWP